Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nepicastat oral- Asieris Pharmaceuticals

Drug Profile

Nepicastat oral- Asieris Pharmaceuticals

Alternative Names: APL-1401; DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117

Latest Information Update: 21 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Asieris Pharmaceuticals; Biotie Therapies Corp.
  • Class Anti-inflammatories; Antineoplastics; Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ulcerative colitis
  • Preclinical Unspecified
  • Discontinued Autoimmune disorders; Cancer; Cocaine-related disorders; Parkinson's disease; Post-traumatic stress disorders

Most Recent Events

  • 21 Sep 2023 Discontinued for Autoimmune disorders in China (PO) (Asieris pharmaceuticals pipeline, September 2023)
  • 30 Aug 2022 Nepicastat licensed to Asieris Pharmaceuticals for non-psychiatric indications
  • 30 Aug 2022 Preclinical trials in Unspecified in China, prior to August 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top